DURECT (NASDAQ:DRRX – Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $6.91 million for the quarter.
DURECT Stock Performance
Shares of NASDAQ DRRX opened at $0.80 on Wednesday. DURECT has a fifty-two week low of $0.70 and a fifty-two week high of $1.88. The stock has a fifty day moving average of $0.80 and a 200-day moving average of $1.04. The stock has a market cap of $24.83 million, a PE ratio of -1.31 and a beta of 0.91.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on DURECT in a research report on Wednesday. They set a “sell” rating for the company.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Featured Stories
- Five stocks we like better than DURECT
- What Are Dividend Champions? How to Invest in the Champions
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Options Trading – Understanding Strike Price
- 3 Must-Own Stocks to Build Wealth This Decade
- 3 Best Fintech Stocks for a Portfolio Boost
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
